Cellectis/2Blades cross-license TAL technologies
French genomics company Cellectis' US subsidiary, Cellectis Plant Sciences (New Brighton, Minnesota), and the US charitable group, the Two Blades Foundation (2Blades - Evanston, Illinois), have entered into a non-exclusive cross-licensing agreement covering TAL (transcription activator like) nuclease technologies. 2Blades receives a licence to Cellectis' TALEN (transcription activator like effector nucleases) technology for non-profit uses, including efforts to support subsistence farming and certain commercial applications related to disease management programmes. Cellectis gains a licence to 2Blades' TAL Code technology related to nucleases for commercial uses in certain specified crops, with an option to extend the deal to additional crops. TAL technologies target genes at precise sites and enable specific regulation of gene expression.